LCTX

AMEX Lineage Cell Therapeutics, Inc.

Nov 10, 2026 · 6:35 PM ET LAST TRADE Market Closed

$1.02 ↓ -0.02 (-1.92%) Trading Down from the previous close of $1.04, $0.05 below the day’s high of $1.07

YTD change: -38.92%
vs 20-day SMA: +2.58%
vs 200-day SMA: -21.98%

Price ranges

Previous day

$1.00 $1.09

open $1.01 close $1.08

+$0.07 (+6.93%)

Today

$1.03 $1.07

open $1.06 now $1.02

-$0.04 (-3.77%)

Past week

$0.96 $1.09

from $1.01 now $1.02

+$0.01 (+0.99%)

Past month

$0.89 $1.09

from $0.95 now $1.02

+$0.07 (+6.91%)

This year

$0.88 $1.99

from $1.67 now $1.02

-$0.65 (-38.92%)

Price & Performance

-0.23 (-17.56%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 63.7% away from all-time highs of $2.81
LCTX is down 39% since the beginning of the year
LCTX is down 44% over the past 12 months
LCTX is up 7% over the past 1 month
12% of all LCTX investors are betting against LCTX
Number of investors short LCTX has gone down 2% versus last month

LCTX reads not so good: price sits above one of the two key moving averages, short interest is falling month over month, the 12-month move is -40.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.13

Earnings momentum -405.6% Quarterly EPS growth

Quarterly change -405.6%

Valuation

P/E ratio N/A

Enterprise value $232.6M

Beta 2.27

Balance sheet & scale

IncomeN/A

Revenue$10.9M

Cash$42.3M

Debt$2.2K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeAMEX

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $258.0M

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$465.23	+1.04%
MRNA	Moderna, Inc.	$269.00	+5.83%
RVMD	Revolution Medicines, Inc.	$200.15	+4.09%
ROIV	Roivant Sciences Ltd.	$40.67	+4.60%
BNTX	BioNTech SE Sponsored ADR	$87.51	+0.00%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.